Comparison of Pegylated Interferon Alfa Therapy in Combination with Tenofovir Alafenamide Fumarate or Tenofovir Disoproxil Fumarate for Treatment of Chronic Hepatitis B Patients

References

• Razavi-Shearer D, Gamkrelidze I, Nguyen MH, Chen D. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383–403. doi:10.1016/S2468-1253(18)30056-6
   PubMed Web of Science ®Google Scholar
• Lampertico P, Agarwal K, Berg T, et al. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398. doi:10.1016/j.jhep.2017.03.021
   PubMed Web of Science ®Google Scholar
• Kim SU, Seo YS, Lee HA, et al. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naive chronic hepatitis B in South Korea. J Hepatol. 2019;71(3):456–464. doi:10.1016/J.JHEP.2019.03.028
   PubMed Web of Science ®Google Scholar
• Buster EHCJ, Hansen BE, Buti M, et al. Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. Hepatology. 2007;46(2):388–394. doi:10.1002/HEP.21723
   PubMed Web of Science ®Google Scholar
• Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus Adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology. 2006:675–684. doi:10.1002/hep.21282
   PubMedGoogle Scholar
• Cheng J, Wang Y, Hou J, et al. Peginterferon alfa-2b in the treatment of Chinese patients with HBeAg-positive chronic hepatitis B: a randomized trial. J Clin Virol. 2014;61(4):509–516. doi:10.1016/j.jcv.2014.08.008
   PubMed Web of Science ®Google Scholar
• Chon YE, Kim DJ, Kim SG, et al. An observational, multicenter, cohort study evaluating the antiviral efficacy and safety in Korean patients with chronic hepatitis B receiving pegylated interferon-Alpha 2a (Pegasys). Medicine. 2016;95(14):e3026. doi:10.1097/MD.0000000000003026
   PubMed Web of Science ®Google Scholar
• Zheng C, Yan H, Zeng J, Cai S, Wu X. Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B. Infect Drug Resist. 2019;12:845–854. doi:10.2147/IDR.S195144
   PubMed Web of Science ®Google Scholar
• Hu C, Song Y, Tang C, et al. Effect of pegylated interferon plus tenofovir combination on higher hepatitis B surface antigen loss in treatment-naive patients with hepatitis B e antigen -positive chronic hepatitis B: a real-world experience. Clin Ther. 2021;43(3):572–581.e3. doi:10.1016/j.clinthera.2020.12.022
   PubMed Web of Science ®Google Scholar
• Ahn SH, Marcellin P, Ma X, et al. Hepatitis B surface antigen loss with tenofovir disoproxil fumarate plus peginterferon Alfa-2a: week 120 analysis. Dig Dis Sci. 2018;63(12):3487–3497. doi:10.1007/s10620-018-5251-9
   PubMed Web of Science ®Google Scholar
• Patrick M, Sang Hoon A, Xiaoli M, et al. Combination of tenofovir disoproxil fumarate and peginterferon α-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology. 2016;150(1):134–144.e10. doi:10.1053/j.gastro.2015.09.043
   PubMed Web of Science ®Google Scholar
• Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology. 2009;49(5):1503–1514. doi:10.1002/HEP.22841
   PubMed Web of Science ®Google Scholar
• Tsai HJ, Chuang YW, Yang SS, Chang YZ, Chang HR, Lee TY. Evaluating the renal safety of tenofovir disoproxil fumarate in hepatitis B patients without chronic kidney disease. J Viral Hepat. 2021;28(11):1579–1586. doi:10.1111/JVH.13603
   PubMed Web of Science ®Google Scholar
• Agarwal K, Brunetto M, Seto WK, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018;68(4):672–681. doi:10.1016/j.jhep.2017.11.039
   PubMed Web of Science ®Google Scholar
• Farag MS, Fung S, Tam E, et al. Effectiveness and renal safety of tenofovir alafenamide fumarate among chronic hepatitis B patients: real-world study. J Viral Hepat. 2021;28(6):942–950. doi:10.1111/jvh.13500
   PubMed Web of Science ®Google Scholar
• Hamzah L, Williams D, Bailey AC, et al. Early safety of tenofovir alafenamide in patients with a history of tubulopathy on tenofovir disoproxil fumarate: a randomized controlled clinical trial. HIV Med. 2020;21(3):198–203. doi:10.1111/hiv.12819
   PubMed Web of Science ®Google Scholar
• Hou J, Ning Q, Duan Z, et al. 3-year treatment of tenofovir alafenamide. Tenofovir disoproxil fumarate for chronic HBV infection in China. J Clin Transl Hepatol. 2021;9(3):324–334. doi:10.14218/JCTH.2020.00145
   PubMed Web of Science ®Google Scholar
• Uchida Y, Nakao M, Yamada S, et al. Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: a 144-week outcome study after switching of the nucleos(t)ide analog. PLoS One. 2022;17(2):e0262764. doi:10.1371/journal.pone.0262764
   PubMed Web of Science ®Google Scholar
• Tian F, Houle SKD, Alsabbagh MW, Wong WWL. Cost-effectiveness of tenofovir alafenamide for treatment of chronic hepatitis B in Canada. Pharmacoeconomics. 2020;38(2):181–192. doi:10.1007/s40273-019-00852-y
   PubMed Web of Science ®Google Scholar
• Chinese Society of Infectious Diseases CMA, Chinese Society of Hepatology CMA. The guidelines of prevention and treatment for chronic hepatitis B (2019 version). Zhonghua Gan Zang Bing Za Zhi. 2019;27(12):938–961. doi:10.3760/cma.j.issn.1007-3418.2019.12.007
   PubMedGoogle Scholar
• Liu J, Wang T, Zhang W, Cheng Y, He Q, Wang FS. Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: a systematic review and meta-analysis. Hepatol Int. 2020;14(6):958–972. doi:10.1007/s12072-020-10099-x
   PubMed Web of Science ®Google Scholar
• Wei W, Wu Q, Zhou J, Kong Y, You H. A better antiviral efficacy found in nucleos(t)ide analog (NA) combinations with interferon therapy than NA monotherapy for HBeag positive chronic hepatitis B: a meta-analysis. Int J Environ Res Public Health. 2015;12(8):10039–10055. doi:10.3390/ijerph120810039
   PubMed Web of Science ®Google Scholar
• Marcellin P, Ahn SH, Chuang WL, et al. Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B. Aliment Pharmacol Ther. 2016;44(9):957–966. doi:10.1111/apt.13779
   PubMed Web of Science ®Google Scholar
• Buti M, Riveiro-Barciela M, Esteban R. Tenofovir alafenamide fumarate: a new tenofovir prodrug for the treatment of chronic hepatitis B infection. J Infect Dis. 2017;216(suppl_8):S792–S796. doi:10.1093/INFDIS/JIX135
   PubMedGoogle Scholar
• Byun KS, Choi J, Kim JH, et al. Tenofovir alafenamide for drug-resistant hepatitis B: a randomized trial for switching from tenofovir disoproxil fumarate. Clin Gastroenterol Hepatol. 2021;20(2):427–437.e5. doi:10.1016/j.cgh.2021.04.045
   PubMed Web of Science ®Google Scholar
• Li M, Zhang L, Xie S, et al. Dynamic changes of cytokine profiles and virological markers associated with HBsAg loss during peginterferon Alpha-2a treatment in HBeAg-positive chronic hepatitis B patients. Front Immunol. 2022;13:892031. doi:10.3389/fimmu.2022.892031
   PubMed Web of Science ®Google Scholar
• Wu FP, Wang YK, Li YP, et al. Clinical analysis of four cases of HBsAg seroconversion in patients with HBeAg-positive chronic hepatitis B after receiving interferon alpha therapy. Zhonghua Gan Zang Bing Za Zhi. 2021;29(6):580–582. doi:10.3760/cma.j.cn501113-20200318-00123
   PubMedGoogle Scholar
• Rosenthal P, Ling SC, Belle SH, et al. Combination of entecavir/peginterferon Alfa-2a in children with hepatitis B e antigen-positive immune tolerant chronic hepatitis B virus infection. Hepatology. 2019;69(6):2326–2337. doi:10.1002/HEP.30312
   PubMed Web of Science ®Google Scholar
• Pondé RAA. Atypical serological profiles in hepatitis B virus infection. Eur J Clin Microbiol Infect Dis. 2013;32(4):461–476. doi:10.1007/s10096-012-1781-9
   PubMed Web of Science ®Google Scholar
• Mathkar PP, Chen X, Sulovari A, Li D. Characterization of hepatitis B virus integrations identified in hepatocellular carcinoma genomes. Viruses. 2021;13(2). doi:10.3390/v13020245
   PubMed Web of Science ®Google Scholar
• Podany AT, Bares SH, Havens J, et al. Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide. AIDS. 2018;32(6):761–765. doi:10.1097/QAD.0000000000001744
   PubMed Web of Science ®Google Scholar
• Kuipery A. Immunomodulation and RNA interference alter hepatitis B virus-specific CD8 T-cell recognition of infected HepG2-NTCP. Hepatology. 2021. doi:10.1002/HEP.32230
   Web of Science ®Google Scholar
• Matsumoto A, Nishiguchi S, Enomoto H, et al. Pilot study of tenofovir disoproxil fumarate and pegylated interferon-alpha 2a add-on therapy in Japanese patients with chronic hepatitis B. J Gastroenterol. 2020;55(10):977–989. doi:10.1007/s00535-020-01707-6
   PubMed Web of Science ®Google Scholar
• Yan L, Zhu C, Li J, et al. Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients. Infect Drug Resist. 2018;11:2001–2009. doi:10.2147/IDR.S175707
   PubMed Web of Science ®Google Scholar
• Li M, Zhang L, Lu Y, et al. Early serum HBsAg kinetics as predictor of HBsAg loss in patients with HBeAg-negative chronic hepatitis B after treatment with pegylated interferonα-2a. Virol Sin. 2021;36(2):311–320. doi:10.1007/s12250-020-00290-7
   PubMed Web of Science ®Google Scholar
• De Ridder F, Sonneveld MJ, Lenz O, Janssen HLA, Talloen W, Hansen BE. Mean HBsAg decline at week 24 of PEG-IFN-based treatment predicts subsequent rate of HBsAg clearance — suggesting a valuable endpoint for early development HBV trials. J Viral Hepat. 2021;28(11):1563–1569. doi:10.1111/jvh.13599
   PubMed Web of Science ®Google Scholar
• Hou FQ, Song LW, Yuan Q, et al. Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon. Theranostics. 2015;5(3):218–226. doi:10.7150/thno.10636
   PubMed Web of Science ®Google Scholar
• Masaki K, Suzuki F, Hara T, et al. Long-term effects of peginterferon alfa-2a therapy in Japanese patients with chronic hepatitis B virus infection. Virol J. 2015;12(1). doi:10.1186/s12985-015-0453-7
   PubMedGoogle Scholar
• Seo Y, Yano Y. Short- and long-term outcome of interferon therapy for chronic hepatitis B infection. World J Gastroenterol. 2014;13284–13292. doi:10.3748/wjg.v20.i37.13284
   PubMedGoogle Scholar